S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Bibliographic Details
Main Authors:	Kim, Seung Tae, Hong, Yong Sang, Lim, Ho Yeong, Lee, Jeeyun, Kim, Tae Won, Kim, Kyu-Pyo, Kim, Sun Young, Baek, Ji Yeon, Kim, Jee Hyun, Lee, Keun-Wook, Chung, Ik-Joo, Cho, Sang-Hee, Lee, Kyung Hee, Shin, Sang Joon, Kang, Hye Jin, Shin, Dong Bok, Lee, Jae Won, Jo, Sook Jung, Park, Young Suk
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289339/

id	pubmed-4289339
recordtype	oai_dc
spelling	pubmed-42893392015-01-11 S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial Kim, Seung Tae Hong, Yong Sang Lim, Ho Yeong Lee, Jeeyun Kim, Tae Won Kim, Kyu-Pyo Kim, Sun Young Baek, Ji Yeon Kim, Jee Hyun Lee, Keun-Wook Chung, Ik-Joo Cho, Sang-Hee Lee, Kyung Hee Shin, Sang Joon Kang, Hye Jin Shin, Dong Bok Lee, Jae Won Jo, Sook Jung Park, Young Suk Research Article BioMed Central 2014-11-26 /pmc/articles/PMC4289339/ /pubmed/25424120 http://dx.doi.org/10.1186/1471-2407-14-883 Text en © Kim et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Kim, Seung Tae Hong, Yong Sang Lim, Ho Yeong Lee, Jeeyun Kim, Tae Won Kim, Kyu-Pyo Kim, Sun Young Baek, Ji Yeon Kim, Jee Hyun Lee, Keun-Wook Chung, Ik-Joo Cho, Sang-Hee Lee, Kyung Hee Shin, Sang Joon Kang, Hye Jin Shin, Dong Bok Lee, Jae Won Jo, Sook Jung Park, Young Suk
spellingShingle	Kim, Seung Tae Hong, Yong Sang Lim, Ho Yeong Lee, Jeeyun Kim, Tae Won Kim, Kyu-Pyo Kim, Sun Young Baek, Ji Yeon Kim, Jee Hyun Lee, Keun-Wook Chung, Ik-Joo Cho, Sang-Hee Lee, Kyung Hee Shin, Sang Joon Kang, Hye Jin Shin, Dong Bok Lee, Jae Won Jo, Sook Jung Park, Young Suk S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
author_facet	Kim, Seung Tae Hong, Yong Sang Lim, Ho Yeong Lee, Jeeyun Kim, Tae Won Kim, Kyu-Pyo Kim, Sun Young Baek, Ji Yeon Kim, Jee Hyun Lee, Keun-Wook Chung, Ik-Joo Cho, Sang-Hee Lee, Kyung Hee Shin, Sang Joon Kang, Hye Jin Shin, Dong Bok Lee, Jae Won Jo, Sook Jung Park, Young Suk
author_sort	Kim, Seung Tae
title	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
title_short	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
title_full	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
title_fullStr	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
title_full_unstemmed	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
title_sort	s-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
description
publisher	BioMed Central
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289339/
_version_	1613175069877469184

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Similar Items